Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01539200
Other study ID # NUD1051
Secondary ID
Status Completed
Phase Phase 3
First received February 15, 2012
Last updated March 25, 2014
Start date March 2012
Est. completion date January 2014

Study information

Verified date March 2014
Source Nestlé
Contact n/a
Is FDA regulated No
Health authority Switzerland: Ethikkommission
Study type Interventional

Clinical Trial Summary

Malnutrition and lack of regular exercise are often found in older adults and have been identified as important risk factors for independence loss and nursing home admission in older community-dwelling adults.

Existing evidence suggests that high protein nutritional supplements can increase skeletal muscle protein synthesis following exercise in older individuals. However, increase of muscle strength by resistance training does not decrease the rate of falls and is not necessarily linked to an improvement of physical function. In contrast to resistance training, T'ai Chi, dance and eurhythmics have been shown to decrease fall incidence and improve mobility and physical function in older adults. The investigators will examine the combination of eurhythmics and high protein nutritional supplements.

The aim of the study is to investigate whether there is an increase in normal walking velocity due to the nutritional supplement on top of once weekly Jacques-Delacroze Eurhythmics training.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date January 2014
Est. primary completion date January 2014
Accepts healthy volunteers No
Gender Both
Age group 65 Years and older
Eligibility Inclusion Criteria:

- Community-dwelling males and females, aged = 65 years

- Able to walk unassisted for 15 meters

- MMSE = 24 points

- Having obtained his/her informed consent

Exclusion Criteria:

- Serum 25(OH) Vitamin D > 100 nmol/L from the blood sampling at Screening

- Current regular (defined as >3x /week) use of high protein oral nutritional supplements

- Milk protein allergy (Lactose intolerance)

- Severe visual impairment (corrected near vision <0.2 in both eyes)

- Severe neurological, orthopaedic, rheumatologic or psychiatric illness causing inability to understand or follow task instructions or to walk 15 meters without assistance (if clinically questionable, final decision will be made by a senior physician)

- Terminal illness with life expectancy less than 12 months, as determined by a physician

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
ONS+JDR
Oral Nutritional Supplement with Jacques-Delacroze Eurythmic training
JDR
Jacques-Delacroze Eurythmic training with placebo ONS

Locations

Country Name City State
Switzerland Basel Mobility Center, Department of Acute Geriatrics Basel

Sponsors (1)

Lead Sponsor Collaborator
Nestlé

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Normal walking velocity The primary objective is to demonstrate in older adults receiving a once weekly Jacques-Delacroze Eurhythmics (JDR) training for six months, that a once daily nutritional supplementation increases normal walking velocity compared with placebo. The primary endpoint of this study is normal walking velocity (NW velocity, in cm/s) six months after the onset of the treatment. 6 months No
Secondary Quality of Life and Nutritional status The secondary objectives of the research project are to compare the effects of the NUDAL intervention versus JDR alone, on changes in functional measures, nutritional status and health-related quality of life baseline, 3 months, 6 months No
Secondary Normal walking velocity Normal walking velocity (NW velocity, in cm/s) will also be evaluated three months after the onset of treatment as a secondary outcome 3 months No